HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.S.-based workflow HACKENSACK, NJ / ACCESS
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models
HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisionsHACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc.
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&DHACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal yearHACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal yearHACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter
This release contains a headline correction from the previous publication.Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions
Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading translational oncology research
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading translational oncology research organization, today announced its financial results
